Skip to Content

Advancements and Emerging Challenges in HER2-Low Treatment

In this MEDtalk, Paolo Tarantino, from the Dana-Farber Cancer Institute, highlights the transformative potential of novel antibody conjugates in treating HER2-positive and HER2-low breast cancer. Through recent trials, Tarantino challenges traditional assumptions about HER2 expression and demonstrates promising outcomes for HER2-low tumours.

Paolo Tarantino

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top